XML 60 R43.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Cerevel (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Sep. 30, 2018 | Sep. 30, 2018 | Oct. 01, 2017 | Sep. 30, 2018 | Oct. 01, 2017
Investment [Line Items] |  |  |  |  |  |  |  |
Pre-tax gain associated with the formation of Cerevel | [2] |  | $ 94,000,000 | [1] | $ 45,000,000 | $ 460,000,000 | [1] | $ 111,000,000
Bain Capital [Member] | Cerevel [Member] |  |  |  |  |  |  |  |
Investment [Line Items] |  |  |  |  |  |  |  |
Pre-tax gain associated with the formation of Cerevel |  | $ 343,000,000 | 343,000,000 |  |  |  |  |
Transfer of Assets [Member] | Neuroscience Assets [Member] | Bain Capital [Member] | Cerevel [Member] |  |  |  |  |  |  |  |
Investment [Line Items] |  |  |  |  |  |  |  |
Committed investment by Bain Capital |  | 350,000,000 | 350,000,000 |  |  | 350,000,000 |  |
Book value of assets transferred |  | $ 0 | $ 0 |  |  | $ 0 |  |
Cerevel Therapeutics [Member] | Cerevel [Member] |  |  |  |  |  |  |  |
Investment [Line Items] |  |  |  |  |  |  |  |
Investment ownership percentage |  | 25.00% |  |  |  |  |  |
[1] | The net gains on investments in equity securities are reported in Other (income)/deductions––net and, for the third quarter and first nine months of 2018, include unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. For additional information, see Note 4.
[2] | The net gains on investments in equity securities for the third quarter of 2018 include unrealized net gains on equity securities of $8 million and, for the first nine months of 2018, include unrealized net gains on equity securities of $344 million, reflecting the adoption of a new accounting standard in the first quarter of 2018. We continue to hold 2.5 million shares of ICU Medical common stock and we recognized unrealized gains of $24 million in the third quarter of 2018 and unrealized gains of $229 million in the first nine months of 2018 related to these remaining shares. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B, Note 2B and Note 7B.

X
- Definition Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 12 -Section 12 -Sentence Column A + Details
Name: | invest_InvestmentLineItems
Namespace Prefix: | invest_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Committed Investment From Collaborator, Amount + References No definition available. + Details
Name: | pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Investment, Ownership Percentage + References No definition available. + Details
Name: | pfe_InvestmentOwnershipPercentage
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount classified as assets attributable to disposal group held for sale or disposed of. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760 + Details
Name: | us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_BainCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_NeuroscienceAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=pfe_CerevelTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |